Yarrow Bioscience, Inc.
Research Yarrow Bioscience, Inc. (YARW) on Bullrun: market cap USD 12.24M, dividend yield 106.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerYARW
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 12.24M
- Dividend yield106.2%
- Financial periodQ2 2026
- RevenueUSD 97.00K
- Net income-USD 3.01M
- Free cash flowUSD 67.57M
Valuation Snapshot
latest market cap is USD 12.24M; dividend yield is 106.2%.
Peer valuation comparison
Latest dividend yield is 106.24% versus a Healthcare sector median of 2.4% (4326.7% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-16 | USD 12.24M | n/a | 109.8% | 20.1 |
| 2025 | 2025-12-31 | USD 19.33M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.48B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 385.01M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 435.27M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 54.62M | n/a | n/a | n/a |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 20.1 USD, yield 106.2%.
About Yarrow Bioscience, Inc.
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Yarrow Bioscience, Inc.'s market cap?
Yarrow Bioscience, Inc.'s market capitalization is USD 12.24M.
Does Yarrow Bioscience, Inc. pay a dividend?
Yarrow Bioscience, Inc. has a dividend yield of 106.2%.
What does Yarrow Bioscience, Inc. do?
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.